Increase in the size of the gingiva is a common feature of gingival disease. Accepted current terminology for this condition is gingival enlargement and gingival overgrowth. These are strictly clinical descriptive terms and avoid the erroneous pathologic connotations of terms used in the past such as hypertrophic gingivitis or gingival hyperplasia. The gingiva and associated soft tissues of the periodontium may be enlarged in response to various interactions between the host and the environment. Although such enlargement usually represents an inflammatory response to bacterial plaque, increased susceptibility as a result of systemic factors or conditions should always be considered during the course of patient evaluation. Systemically related gingival enlargements include, but are not limited to, scurvy, leukemia, puberty, pregnancy, multisystem syndromes and selected drugs and/or agents. In addition, fibrotic gingival enlargement has been reported and is believed to be the result of a genetic predisposition (for example hereditary or familial gingival enlargement). However an idiopathic variant that has not been associated with genetic linkage or cause has been described. Of the predisposing factors associated with the gingival enlargement, selected anticonvulsant drug, Calcium channel blockers and a potent immunosuppressant (Cyclosporine A) have generated the most investigative attention in the scientific community. This book will help understand the mechanism of drug induced gingival enlargement and its treatment.
Table of Contents
INTRODUCTION
CLASSIFICATION
CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT
PATHOGENESIS OF DRUG INDUCED GINIGVAL ENLARGEMENT
HISTOPATHOLOGY OF DRUG INDUCED GINGIVAL ENLARGEMENT
ETIOLOGY OF DRUG-INDUCED GINGIVAL ENLARGEMENT
DRUGS ASSOCIATED WITH GINGIVAL ENLARGEMENT
INDICES
MANAGEMENT
SUMMARY AND CONCLUSION
Objectives and Topics
The primary objective of this work is to provide a comprehensive analysis of drug-induced gingival enlargement, a condition frequently associated with anticonvulsants, calcium channel blockers, and immunosuppressants. The research explores the complex, multifactorial etiology and pathogenesis of this overgrowth, evaluating the clinical features, histological characteristics, and the role of individual genetic predisposition and local inflammatory factors in its manifestation and management.
- Pharmacological classes associated with gingival overgrowth
- Pathogenic mechanisms at the cellular level, focusing on calcium ion flux
- Clinical diagnostic criteria and standardized indices for gingival enlargement
- Impact of systemic medications on periodontal health and tissue homeostasis
- Strategies for clinical management, including drug substitution and surgical intervention
Excerpt from the Book
PATHOGENESIS OF DRUG INDUCED GINIGVAL ENLARGEMENT
Despite their pharmacological diversity, the three major drugs causing gingival overgrowth, namely; anticonvulsants, calcium channel blockers, and immunosuppressants; have similar mechanism of action at the cellular level, where they inhibit intracellular calcium ion influx. The action of these drugs on calcium and sodium ion flux may prove to be the key in understanding why three dissimilar drugs have a common side effect upon a secondary target tissue, such as gingival connective tissue. An appraisal of the various investigations into the pathogenesis of drug-induced gingival overgrowth supports the hypothesis that it is multifactorial. Plaque scores and gingival inflammation appear to exacerbate the expression of drug-induced gingival overgrowth, irrespective of the initiating drug. The severity of gingival enlargement in patients taking medications correlates well with poor plaque control and is commensurate with the degree of plaque induced inflammation. The importance of plaque as a cofactor in the etiology of drug-associated gingival enlargement has been recognized in the most recent classification system for periodontal diseases. In this classification, “drug induced gingival enlargements” are categorized as plaque-induced gingival diseases modified by medications.
Summary of Chapters
INTRODUCTION: Defines gingival enlargement as a condition induced by specific medication classes and discusses the history and multifactorial nature of the disorder.
CLASSIFICATION: Categorizes gingival enlargements based on etiologic factors, pathologic changes, and clinical distribution.
CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT: Describes the progression, appearance, and typical location of gingival overgrowth, as well as associated risk factors.
PATHOGENESIS OF DRUG INDUCED GINIGVAL ENLARGEMENT: Explores the cellular and molecular mechanisms, including the role of fibroblasts, cytokines, and matrix metalloproteinases.
HISTOPATHOLOGY OF DRUG INDUCED GINGIVAL ENLARGEMENT: Details the microscopic structural changes in connective tissue and epithelium associated with the condition.
ETIOLOGY OF DRUG-INDUCED GINGIVAL ENLARGEMENT: Provides a historical perspective and reviews various scientific theories regarding the cause of the overgrowth.
DRUGS ASSOCIATED WITH GINGIVAL ENLARGEMENT: Lists and categorizes the specific pharmacological agents known to cause gingival overgrowth.
INDICES: Outlines the various standardized clinical scoring methods used to measure the severity of gingival overgrowth.
MANAGEMENT: Discusses clinical approaches to treatment, including drug substitution, plaque control, and surgical procedures like gingivectomy.
SUMMARY AND CONCLUSION: Synthesizes the findings, emphasizing the need for a multifactorial understanding and early identification of susceptible patients.
Keywords
Gingival enlargement, drug-induced gingival overgrowth, phenytoin, cyclosporine, calcium channel blockers, nifedipine, pathogenesis, gingival fibroblasts, plaque control, gingivectomy, periodontal disease, drug substitution, inflammation, connective tissue, clinical indices.
Frequently Asked Questions
What is the primary focus of this work?
This work focuses on the clinical and pathological aspects of drug-induced gingival enlargement, a condition caused by specific medications, and evaluates current theories regarding its development.
Which medication classes are mainly linked to this condition?
The condition is primarily induced by three main classes: anticonvulsants (like phenytoin), immunosuppressants (like cyclosporine), and antihypertensive calcium channel blockers (like nifedipine).
What is the central research question?
The central question involves understanding why drugs with diverse pharmacological actions produce similar gingival tissue changes, and investigating the underlying pathogenic mechanisms.
How is the condition clinically managed?
Management involves a combination of non-surgical plaque control, potential drug substitution, and surgical intervention such as gingivectomy if functional or aesthetic concerns arise.
What are the key themes addressed in the text?
Key themes include the multifactorial nature of the pathogenesis, the importance of genetic susceptibility, the role of local inflammation, and the impact of these drugs on cellular calcium homeostasis.
Which keywords best characterize this research?
Key terms include drug-induced gingival overgrowth, fibroblast activity, phenytoin, cyclosporine, nifedipine, and plaque-induced inflammation.
Is there a correlation between drug dosage and the severity of the overgrowth?
Research indicates that while some studies suggest a correlation, most evidence shows that the severity of overgrowth is not always directly related to drug dosage, suggesting other individual and environmental factors are at play.
Why is the genetic aspect of fibroblasts considered relevant?
The text suggests that specific subpopulations of gingival fibroblasts may be genetically predisposed to exhibit a fibrogenic response when exposed to certain medications, explaining why some patients develop the condition while others do not.
- Arbeit zitieren
- Ketaki Kanade (Autor:in), 2018, Drug Induced Gingival Enlargement, München, GRIN Verlag, https://www.hausarbeiten.de/document/443002
